Spearheading Immunotherapies

Harpoon is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases.

At the heart of Harpoon’s approach is a novel antibody-derived platform called TriTAC® (Tri-specific T cell Activating Construct) designed for targeted penetration and destruction of solid tumors and hematologic malignancies, and engineered to bind to human serum albumin for improved therapeutic schedule and patient convenience.

Management Team

Board of Directors

Scientific Advisory Board


Our Partners

Harpoon has an agreement with F. Hoffmann-La Roche for the supply of atezolizumab. Under this agreement, Harpoon is the sponsor of the trial, and Roche supplies atezolizumab for Harpoon’s ongoing Phase 1/2 trial of HPN328. Additionally, Harpoon and AbbVie are collaborating under a discovery collaboration for up to six targets, leveraging Harpoon’s TriTAC and ProTriTAC platforms to produce novel T cell engagers for solid tumors and hematologic malignancies.